Patch testing for nonimmediate cutaneous adverse drug reactions - 13/01/18
Doi : 10.1016/j.jaad.2017.08.049
Zachary Zinn, MD a, b, ⁎ 
, Swapna Gayam, MD b, Malcolm P. Chelliah, BA c, Golara Honari, MD a, Joyce Teng, MD, PhD a
, Swapna Gayam, MD b, Malcolm P. Chelliah, BA c, Golara Honari, MD a, Joyce Teng, MD, PhD a a Stanford University, Palo Alto, California
b West Virginia University, Morgantown, West Virginia
c Stanford University School of Medicine, Palo Alto, California
∗Correspondence to: Zachary Zinn, MD, University Town Centre-3rd Floor, Dermatology, 6040 University Town Centre Drive, Morgantown, WV 26501University Town Centre-3rd FloorDermatology6040 University Town Centre Drive, MorgantownWV26501
| Drs Zinn and Gayam are co-first authors. |
|
| Funding sources: None. |
|
| Conflicts of interest: None declared. |
|
| Reprints not available from the authors. |
© 2017
American Academy of Dermatology, Inc.. Publié par Elsevier Masson SAS. Tous droits réservés.
Vol 78 - N° 2
P. 421-423 - février 2018 Retour au numéro
Article précédent
- Predicting the incidence and timing of central nervous system disease in metastatic melanoma: Implications for surveillance and preventative therapy
- Gary B. Deutsch, Richard Tyrell, Samuel Yost, Mariel B. Deutsch, Garni Barkhoudarian, Daniel F. Kelly, Mark B. Faries
- Accuracy of death certification in cutaneous squamous cell carcinoma: A retrospective case review
- David M. Wang, Robert J. Besaw, Pritesh S. Karia, Chrysalyne D. Schmults
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?